Literature DB >> 8977776

Levator transposition procedure: a review of 35 cases.

R M Manners1, P Rosser, J R Collin.   

Abstract

BACKGROUND: Levator transposition is used as a unilateral procedure for patients with both ptosis and aberrant movements of the eyelid. Muscular neurotisation occurs in the transposed levator muscle and thus some levator function is restored.
METHOD: We reviewed 35 patients who had undergone a levator transposition procedure.
RESULTS: Twenty-eight patients had jaw-winking ptosis, three had cyclic oculomotor palsy and four had a third nerve palsy with aberrant regeneration. The follow-up period was between 1 and 39 months (mean 12 months). Eighteen patients were followed up for at least 12 months and their results were analysed as a separate group.
CONCLUSIONS: The levator function attained following transposition is related to the pre-operative voluntary function and this relationship is statistically significant (Wilcoxon test p < 0.001). Maximal levator function may not be achieved until 12 months post-operatively. The procedure is successful in abolishing aberrant eyelid movements and treating ptosis but the majority of patients require an additional levator resection to achieve a satisfactory lid height.

Entities:  

Mesh:

Year:  1996        PMID: 8977776     DOI: 10.1038/eye.1996.124

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Management of morderate-to-severe Marcus-Gunn syndrome by anastomosis of levator and frontal muscles.

Authors:  Nan Xiang; Wei-Kun Hu; Bin Li; Rong Liu
Journal:  Int J Ophthalmol       Date:  2010-12-18       Impact factor: 1.779

2.  Aetiology and surgical treatment of childhood blepharoptosis.

Authors:  V Lee; H Konrad; C Bunce; C Nelson; J R O Collin
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

3.  Frontalis sling surgery: A treatment modality for cyclic oculomotor nerve palsy.

Authors:  Smriti Bansal; Sima Das
Journal:  Saudi J Ophthalmol       Date:  2017-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.